within Pharmacolibrary.Drugs.ATC.S;

model S01EB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluostigmine is a synthetic organophosphate compound and a potent acetylcholinesterase inhibitor, related to physostigmine. It was historically investigated for its use in glaucoma management as a miotic agent in ophthalmology but is not currently approved for therapeutic use and is rarely used in clinical practice due to toxicity concerns.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data were found for fluostigmine in humans. The following parameters are estimated based on analogous acetylcholinesterase inhibitors used in ophthalmology, such as physostigmine and neostigmine.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01EB07;
